Quick Answer
Damora Therapeutics, Inc. reported Common Stock Shares Outstanding of 1.60 million shares for the year ending 2025.
- Damora Therapeutics, Inc. showed an increase of +21.3% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Damora Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: 259,966 shares | Q1 2021: 25.26 million shares | Q2 2021: 25.26 million shares | Q3 2021: 25.26 million shares | Q1 2022: 25.26 million shares | Q2 2022: 25.34 million shares | Q3 2022: 25.58 million shares | Q1 2023: 25.67 million shares | Q2 2023: 27.02 million shares | Q3 2023: 27.11 million shares | Q1 2024: 27.11 million shares | Q2 2024: 27.12 million shares | Q3 2024: 1.25 million shares | Q1 2025: 1.32 million shares | Q2 2025: 1.32 million shares | Q3 2025: 1.33 million shares.
- Over the full 7 years of available data (2019 to 2025), Damora Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 514.4%.
- Historical annual values: Fiscal year 2025: 1.60 million shares | Fiscal year 2024: 1.32 million shares | Fiscal year 2023: 1.08 million shares | Fiscal year 2022: 25.65 million shares | Fiscal year 2021: 25.26 million shares | Fiscal year 2020: 25.26 million shares | Fiscal year 2019: 259,966 shares.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: